Trial reportThe clinical respiratory journal2025
The Value of Soluble Urokinase Plasminogen Activator Receptor (suPAR) as Predictive Tool in Hospitalised Patients With Community-Acquired Pneumonia (CAP).
Trial report in The clinical respiratory journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01964495 (Reduction of Antibiotic Therapy by Biomakers in Patients With CAP Episodes), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Reduction of Antibiotic Therapy by Biomakers in Patients With CAP Episodes (REDUCE Study)
Who cites it
2 citing papers in PubMed.
- The Value of Soluble Urokinase Plasminogen Activator Receptor (suPAR) as Predictive Tool in Hospitalised Patients With Community-Acquired Pneumonia (CAP).The clinical respiratory journal · 2025Trial
- Soluble Urokinase Plasminogen Activator Receptor (suPAR) Predicts 28-Day and 90-Day Mortality in Emergency Department Patients with Chest Pain, Dyspnoea, or Abdominal Pain.Diagnostics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundSoluble urokinase plasminogen activator receptor (suPAR) is a biomarker elevated in severely ill patients, but its prognostic value in community-acquired pneumonia (CAP) remains unclear. This study aimed to evaluate suPAR's prognostic role for CAP severity compared to other biomarkers and severity scores.
methodsA total of 204 hospitalised CAP patients were enrolled. C-reactive protein (CRP), procalcitonin (PCT), suPAR, CURB-65 and Pneumonia Severity Index (PSI) scores were measured at admission, and patients were followed for 365 days. The primary outcome was the relationship between suPAR levels and CAP severity based on IDSA/ATS guidelines. Secondary outcomes included time to clinical stability (TTCS), length of stay (LOS) and mortality.
resultsAmong 204 patients, 174 (85%) had non-severe and 30 (15%) had severe CAP. SuPAR levels were not associated with severe CAP (OR 1.03, 95% CI 0.88-1.21; AUC 0.53). Unlike the PSI and CURB-65 scores, suPAR did not correlate with TTCS (HR PSI 0.80, HR CURB-65 0.86), though all three markers were correlated to LOS (AUC suPAR 0.61). Only suPAR was significantly associated with 30-day mortality (HR 1.51, AUC 0.68).
conclusionsThe prognostic value of suPAR for CAP severity is low, and it does not provide additional prognostic benefit over the CURB-65 or PSI scores in predicting CAP severity. While it has moderate predictive ability for 30-day mortality, its utility for predicting LOS or TTCS is low.
trial registrationClinicalTrials.gov identifier: NCT01964495.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.